E2f1 and RB are common mediators of the inhibitory effects prompted by the combination of Mifepristone and Palbociclib on breast cancer cells expressing progesterone receptor Isoform A
Revista
Acceso abierto
Revista
CONICET Digital
Palbociclib (PALBO), a CDK 4/6 inhibitor, is currently used in combination with endocrine therapy targeting estrogen receptors to treat advanced luminal breast cancer. However, with time tumors become resistant to these ...
Idioma eng
Acceso abiertoRuta libre sin proxy. Acceso recomendado cuando no hay suscripción activa.
Open Access